MarketCap
Facebook
X
TelegramGeschäftsbericht 2021
hinzugefügt 23.12.2023
Amryt Pharma plc Current Ratio 2011-2026 | AMYT
Current Ratio Jährlich Amryt Pharma plc
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| 1.78 | 1.14 | 1.33 | 0.956 | - | - | - | - | - | - | - |
Alle Zahlen in USD-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 1.78 | 0.956 | 1.3 |
Current Ratio Vierteljährlich Amryt Pharma plc
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | 1.78 | - | - | - | 1.14 | - | - | - | 1.33 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Alle Zahlen in USD-Währung
Indikatorspanne aus vierteljährlicher Berichterstattung
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 1.78 | 1.14 | 1.42 |
Current Ratio anderer Aktien in der Pharmaeinzelhändler
| Name | Current Ratio | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
1.02 | - | 2.43 % | $ 254 M |  Germany |
 |
Aligos Therapeutics
ALGS
|
2.53 | $ 8.71 | -0.11 % | $ 86.1 M |  USA |
 |
Allakos
ALLK
|
3.26 | - | - | $ 28.6 M | USA |
 |
Alterity Therapeutics Limited
ATHE
|
7.02 | $ 3.6 | -1.64 % | $ 8.66 B |  Australia |
 |
Aptinyx
APTX
|
2.35 | - | -39.0 % | $ 4.57 M | USA |
 |
Aravive
ARAV
|
1.21 | - | -13.39 % | $ 1.45 M | USA |
 |
Anavex Life Sciences Corp.
AVXL
|
11.6 | $ 3.29 | 5.63 % | $ 281 M | USA |
 |
I-Mab
IMAB
|
8.96 | - | - | $ 866 M |  China |
 |
AlloVir
ALVR
|
2.84 | - | 4.14 % | $ 49.1 M | USA |
|
Applied Molecular Transport
AMTI
|
2.31 | - | - | $ 10.1 M | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
3.59 | - | - | $ 40.3 B | USA |
 |
Genfit SA
GNFT
|
0.922 | - | 2.54 % | $ 160 B |  France |
 |
Biophytis SA
BPTS
|
1.34 | - | -13.47 % | $ 169 M | France |
 |
Brainstorm Cell Therapeutics
BCLI
|
0.0929 | - | -2.5 % | $ 5.88 M | USA |
 |
Applied Therapeutics
APLT
|
0.762 | - | - | $ 8.42 M | USA |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
1.02 | - | -1.52 % | $ 24.7 M | USA |
 |
BeiGene, Ltd.
BGNE
|
2.14 | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
BioNTech SE
BNTX
|
7.95 | $ 99.62 | 3.02 % | $ 27.2 B | Germany |
 |
bluebird bio
BLUE
|
1.46 | - | - | $ 546 M | USA |
 |
Burford Capital Limited
BUR
|
2.14 | $ 4.74 | 5.46 % | $ 746 M |  Britain |
 |
Midatech Pharma plc
MTP
|
2.68 | - | -18.52 % | $ 27.3 M | Britain |
 |
Cabaletta Bio
CABA
|
3.11 | $ 3.26 | 1.72 % | $ 328 M | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
1.94 | $ 21.51 | 0.7 % | $ 1.01 B | USA |
 |
Checkpoint Therapeutics
CKPT
|
0.372 | - | - | $ 169 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
1.04 | - | - | - |  Russia |
 |
Adverum Biotechnologies
ADVM
|
1.65 | - | - | $ 86.2 M | USA |
 |
Advaxis
ADXS
|
5.93 | - | -9.65 % | $ 45.9 M | USA |
 |
Clearside Biomedical
CLSD
|
0.681 | - | - | $ 25.3 M | USA |
 |
Aeterna Zentaris
AEZS
|
1.22 | - | 5.93 % | $ 314 M |  Canada |
 |
AgeX Therapeutics
AGE
|
0.995 | - | -10.17 % | $ 12.2 K | USA |
 |
Aeglea BioTherapeutics
AGLE
|
12.4 | - | - | $ 1.01 B | USA |
 |
Akebia Therapeutics
AKBA
|
1.09 | $ 1.55 | 5.1 % | $ 399 M | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
1.79 | - | - | $ 26.5 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
2.76 | $ 3.05 | 4.45 % | $ 5.02 M |  Israel |
 |
Aquestive Therapeutics
AQST
|
0.827 | $ 4.21 | 0.48 % | $ 450 M | USA |
 |
Arcutis Biotherapeutics
ARQT
|
1.78 | $ 25.28 | 4.79 % | $ 3.22 B | USA |
 |
Chimerix
CMRX
|
10.8 | - | - | $ 756 M | USA |
 |
Concert Pharmaceuticals
CNCE
|
3.11 | - | - | $ 401 M | USA |
 |
AIkido Pharma
AIKI
|
2.59 | - | 1.93 % | $ 17.4 M | USA |
 |
Celldex Therapeutics
CLDX
|
10.4 | $ 33.61 | 3.13 % | $ 2.23 B | USA |
 |
Autolus Therapeutics plc
AUTL
|
1.43 | $ 1.51 | 2.44 % | $ 402 M | Britain |
 |
Aptose Biosciences
APTO
|
0.269 | - | -45.71 % | $ 1.2 M | Canada |
 |
Cidara Therapeutics
CDTX
|
4.17 | - | - | $ 1.41 B | USA |
 |
AVROBIO
AVRO
|
15.9 | - | 1083.1 % | $ 745 M | USA |
 |
CNS Pharmaceuticals
CNSP
|
2.1 | $ 2.46 | -2.19 % | $ 1.09 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
6.43 | - | - | $ 7.46 M | Israel |
 |
AstraZeneca PLC
AZN
|
1.75 | - | - | $ 96.9 B | Britain |
 |
Akero Therapeutics
AKRO
|
10.9 | - | - | $ 3.67 B | USA |
 |
CTI BioPharma Corp.
CTIC
|
0.878 | - | - | $ 1.2 B | USA |
 |
CureVac N.V.
CVAC
|
2.47 | - | - | $ 867 M | Germany |